TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36336684
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity measures (HOMA2S, Matsuda ISI, MinMod SI)
Study: 36336899
Drug: Tumor treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor treating fields (TTFields) with concurrent chemoradiation
Study: 36337437
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) 500 mg/day for 6 weeks
Study: 36337437
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) 500 mg/day
Study: 36337613
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch type 4 (RS4) intake of 12 g/day for 12 weeks
Study: 36337904
Drug: Long drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long drug-eluting stents (DES)
Study: 36337904
Drug: Spot drug-eluting
Normalized name: Cold Spot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spot drug-eluting stents (DES)
Study: 36338362
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stent (DES)
Study: 36338362
Drug: First-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation drug-eluting stent (DES)
Study: 36338415
Drug: Persistent high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistent high RIR (hsCRP ≥2 mg/L)
Study: 36338481
Drug: 7% solution
Normalized name: Aminosyn 7% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% solution of xylitol
Study: 36338481
Drug: 7% solution
Normalized name: Aminosyn 7% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% solution of free sugars (glucose, fructose, sucrose)
Study: 36338546
Drug: DDK inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDK inhibitor
Study: 36338546
Drug: WEE1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WEE1 inhibitor
Study: 36338743
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose (booster) of COVID-19 mRNA vaccination (Pfizer-BioNTech or Moderna)
Study: 36338743
Drug: First two
Approvals — FDA: no, EMA: no, PMDA: no
Description: First two doses of COVID-19 mRNA vaccination
Study: 36339126
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus aspirin (T+A)
Study: 36339533
Drug: Compound methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound methyl salicylate liniment (Ammeltz)
Study: 36339707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of spa rehabilitation with ubiquinol therapy
Study: 36339926
Drug: Savolitinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib, a selective MET inhibitor
Study: 36342102
Drug: FS118 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS118 (800 μg to 0.3 mg/kg followed by 1 to 20 mg/kg weekly)
Study: 36342102
Drug: FS118 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS118 (1 mg/kg or greater)
Study: 36342104
Drug: Pfizer/BioNTech BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer/BioNTech BNT162b2 or Oxford/AstraZeneca ChAdOx1 vaccine; 99 patients received at least one dose of vaccine prior to, or during the study.
Study: 36342116
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg body weight)
Study: 36342173
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy in cohort 1
Study: 36342173
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy in cohort 2
Study: 36342342
Drug: Adjuvant abemaciclib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant abemaciclib combined with endocrine therapy (ET)
Study: 36342853
Drug: Investigational extended-wear
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational extended-wear insulin infusion set (IIS)
Study: 36342853
Drug: Conventional Teflon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Teflon angled insulin infusion set (IIS)
Study: 36342912
Drug: Praziquantel (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (two doses)
Study: 36342972
Drug: Antidiabetic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic medications (ADMs) including biguanides (metformin), sulfonylureas (gliclazide, glibenclamide, glimepiride, glipizide, glyclopyramide), insulin (premix, basal, basal/bolus), DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin)
Study: 36343674
Drug: Cutoff values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutoff values for rectal submucosa in CD
Study: 36343674
Drug: Cutoff values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutoff values for rectal mucosa in UC
Study: 36344555
Drug: Nuclear Transport
Normalized name: oxymetazoline hydrochloride Ophthalmic Solution [Ocuclear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuclear Transport Checkpoint Inhibitor (NTCI) topical treatment
Study: 36344663
Drug: Moderate correlations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate correlations (P < 0.001) of the 24 h urinary Na/K ratio with 24 h urinary Na and K excretion
Study: 36344711
Drug: Nanoliposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan (nal-IRI) at 70 mg/m² during HIPEC
Study: 36346005
Drug: Educational interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational interventions (face-to-face or e-learning focusing on infective area, basic gestures, COVID clinical management and intensive care medicine)
Study: 36346044
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and fluorouracil (infusional fluorouracil of 200 mg/m2)
Study: 36346118
Drug: FIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT with a positivity threshold of >15 mcg haemoglobin/g faeces, interval between rounds varied between 1.5 and 3.5 years
Study: 36346229
Drug: Islatravir 60
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 60 mg administered orally
Study: 36346366
Drug: ERK-MAPK inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERK-MAPK inhibitor (ulixertinib) in combination with CDK4/6 inhibitor (palbociclib)
Study: 36346366
Drug: Novel therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapeutic combinations validated using siRNA and small-molecule inhibitors
Study: 36346679
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine (IM) intervention, single 30-minute session combining acupuncture, mind-body, and/or manual-movement modalities.
Study: 36347128
Drug: Endovascular techniques
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular techniques for treatment of ALI
Study: 36350312
Drug: Molibresib 75
Normalized name: Molibresib
DrugBank: Molibresib (DB16239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molibresib 75 mg daily for MDS
Study: 36350312
Drug: Molibresib 60
Normalized name: Molibresib
DrugBank: Molibresib (DB16239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molibresib 60 mg daily for CTCL
Study: 36350359
Drug: Total vitamin
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total vitamin D intake from food and supplements
Study: 36350362
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy Device
Study: 36350598
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Alcohol Use Disorder
Study: 36350899
Drug: cabazitaxel chemotherapy
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cabazitaxel chemotherapy
Study: 36351064
Drug: Welch Allyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Welch Allyn Connex® Spot Monitor/Hillrom Connecta™ automated solution
Study: 38269049
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) therapy
Study: 36351728
Drug: Remifentanil dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil dose titration
Study: 36351741
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 30 mL 2.5 mg/mL ropivacaine and 0.3 mL gadolinium.
Study: 36351814
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) and/or endovascular treatment (EVT)
Study: 36351931
Drug: CoVLP+AS03 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoVLP+AS03 vaccine (3.75 µg CoVLP/dose + AS03), administered as two intramuscular doses, 21 days apart.
Study: 36352028
Drug: AZD8931 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 (160 mg bd) with FOLFIRI
Study: 36352054
Drug: Aprocitentan 25
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 25 mg single oral dose
Study: 36352103
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL t.i.d. treatment with a full-spectrum, high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 mg/mL Δ-9-tetrahydrocannabinol)
Study: 36353661
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment sequences including ABI-DOCE, ABI-ENZA, ABI-RAD, DOCE-ABI, DOCE-CABA, DOCE-ENZA, ENZA-DOCE
Study: 36355054
Drug: AZD8205 (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8205 (3.5 mg/kg single administration)
Study: 36355054
Drug: AZD5305 (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5305 (in combination with AZD8205)
Study: 36355259
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation with Tumor Treating Fields (TTFields, 200 kHz), standard concurrent temozolomide (TMZ), and scalp-sparing radiation (60 Gy in 30 fractions). Maintenance therapy included standard TMZ and continuation of TTFields.
Study: 36355775
Drug: M72/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01 vaccine (two immunizations)
Study: 38296630
Drug: Acetazolamide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (375 mg/day)
Study: 36356418
Drug: Internal mammary
Normalized name: Bovine internal mammary artery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal mammary chain radiation therapy (RT)
Study: 36356418
Drug: Normofractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normofractionated radiation therapy (RT)
Study: 36356599
Drug: Non-viral precision
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-viral precision T cell receptor replacement
Study: 36356972
Drug: Methylprednisolone 80
Normalized name: methylPREDNISolone 80 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering
Study: 36356972
Drug: Conventional dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional dexamethasone (6 mg daily for 7-10 days)
Study: 37270762
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (cilta-cel) therapy
Study: 36357392
Drug: Branaplam (splicing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branaplam (splicing modulator)
Study: 36357415
Drug: Neoadjuvant camrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant camrelizumab plus concurrent chemoradiotherapy
Study: 36357877
Drug: PrEP awareness
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP awareness influenced by external factors such as social media and community knowledge about HIV treatment and prevention.
Study: 36357877
Drug: Joining the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joining the HIV vaccine trial preparedness study.
Study: 36358702
Drug: Calcium electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium electroporation (CaEP) with intratumoral injection of calcium gluconate followed by reversible electroporation.
Study: 36358702
Drug: Calcium electroporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium electroporation (CaEP) treatment.
Study: 36360766
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy sleep programme sessions (2 sessions)
Study: 36367717
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine uptake
Study: 36369507
Drug: Telehealth support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth support comprising automated twice-weekly telephone calls with a specialist nurse triaging alerts.
Study: 36369848
Drug: EDP-297 20-600
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-297 20-600 μg single doses
Study: 36369848
Drug: EDP-297 5-90
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-297 5-90 μg once daily for 14 days
Study: 36369848
Drug: EDP-297 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-297 (all doses)
Study: 36369848
Drug: EDP-297 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-297 (60 μg MAD)
Study: 36370233
Drug: Fixed-combination bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort), one drop per eye every evening
Study: 36370233
Drug: Fixed-combination bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort)
Study: 36370742
Drug: Olutasidenib monotherapy
Normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olutasidenib monotherapy (150 mg once daily, 150 mg twice per day, 300 mg once daily)
Study: 36370742
Drug: Olutasidenib in
Normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olutasidenib in combination with azacitidine (75 mg/m2)
Study: 36371226
Drug: Compartmental radioimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly, 100 radioiodinated omburtamab injections at a recommended phase 2 dose of 1850 MBq/injection.
Study: 36371226
Drug: Compartmental radioimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly.
Study: 36371408
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg CoVLP+AS03
Study: 36372245
Drug: AT-001 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-001 (1000 mg BID)
Study: 36372245
Drug: AT-001 (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-001 (1500 mg BID)
Study: 36372356
Drug: MSC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MSC infusion on the day of leukocyte recovery to 1000 cells/μL (engraftment, day E0)
Study: 36372356
Drug: MSC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MSC infusion on day E0
Study: 36372442
Drug: Fostemsavir co-administration
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir co-administration with hormone therapy
Study: 36372442
Drug: Fostemsavir with
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir with combined oral contraceptives (COCs)
Study: 36372442
Drug: Other oestrogen-based
Normalized name: Other estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oestrogen-based therapies with fostemsavir
Study: 36372873
Drug: ≥ 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥ 50% reductions in CSF ctDNA concentrations after 8 weeks of treatment
Study: 36373234
Drug: Sex-hormone-binding globulin
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sex-hormone-binding globulin in PCOS patients
Study: 36373249
Drug: Partially HLA-matched,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109) in combination with other antiviral agents
Study: 36375653
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of N20Amp decrease and N20Amp < 1.23 µV at 72 h
Study: 36375971
Drug: Outpatient parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient parenteral antimicrobial therapy (OPAT)
Study: 36375981
Drug: FLOT chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin plus docetaxel)
Study: 36375981
Drug: ECF/ECX chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECF/ECX chemotherapy (epirubicin, cisplatin plus fluorouracil or capecitabine)
Study: 36376393
Drug: ChulaCov19 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChulaCov19 vaccine at 10 μg
Study: 36376393
Drug: ChulaCov19 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChulaCov19 vaccine at 25 μg
Study: 36376393
Drug: ChulaCov19 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChulaCov19 vaccine at 50 μg
Study: 36376636
Drug: Combination rationale
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination rationale (n=1786)
Study: 37348519
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 μg)
Study: 36376733
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 μg and 100 μg)
Study: 36376833
Drug: VEGF rs3025039
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF rs3025039 CC genotype
Study: 36376960
Drug: Peer-supported intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-supported intervention targeting diabetes and medication beliefs, communication, and self-efficacy skills; details on dosage and duration not specified.
Study: 36376960
Drug: Peer-supported intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-supported intervention; details on dosage and duration not specified.
Study: 36378074
Drug: BA.4/BA.5-adapted mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA.4/BA.5-adapted mRNA booster vaccine
Study: 36378074
Drug: BA.1-adapted mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA.1-adapted mRNA vaccine (bivalent format: wild-type + BA.1)
Study: 36378074
Drug: Bivalent wild-type
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent wild-type + BA.4/BA.5 vaccine
Study: 36378074
Drug: Bivalent wild-type
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent wild-type + Omicron BA.4/BA.5 vaccine
Study: 36378548
Drug: SRA737 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRA737 (500 mg) combined with low-dose gemcitabine (250 mg/m2)
Study: 36379002
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg intravenously once every 3 weeks
Study: 36379575
Drug: Baseline characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline characteristics (absence of MRI sacroiliitis and hs-CRP > 3 mg/L)
Study: 36379595
Drug: Delayed cytoreductive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed cytoreductive surgery (≥5 cycles of chemotherapy)
Study: 36379595
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery (after 3-4 cycles of chemotherapy)
Study: 36379595
Drug: No surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgery (≥5 cycles of chemotherapy alone)
Study: 36379880
Drug: R-chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-chemotherapy
Study: 36379880
Drug: G-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-chemotherapy
Study: 36381503
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccine during ongoing siponimod treatment (cohort 1)
Study: 36381503
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccine during siponimod treatment interruption (cohort 2)
Study: 36381503
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccine while on other DMTs or no therapy (cohort 3)